The Japanese Pharmaceutical Companies Outlook: An analysis of key players and growth strategies

Executive Summary

The Japanese Pharmaceutical Companies Outlook: An analysis of key players and growth strategies evaluates the strengths and weaknesses of the top 10 Japanese pharmaceutical firms’ strategic and financial positions, marketed portfolios and pipeline compounds. This report will enable you to assess the market dynamics within the Japanese pharma market and understand how companies are positioning themselves at a time of significant change in their domestic market. The Japanese pharmaceutical market is the second largest in the world, behind only the US, with estimated sales of $52bn in 2002. While it makes it an attractive target for Western companies’ expansion plans, low market growth (1% in 2002) has made the operating environment increasingly difficult for domestic players. Coupled with ongoing regulatory reforms and drug price cuts, which are largely intended to reduce the government’s healthcare bill, Japanese companies are being forced to adapt their operating strategies.